Xenoma, Inc.

Based in Tokyo, Japan, Xenoma, Inc. provides innovative healthcare solutions through its advanced e-skin smart apparel, enabling seamless health monitoring and enhancing patient care. Founded in 2015 in Tokyo, Japan, Xenoma, Inc. specializes in digital health solutions with a focus on wearable technology for health monitoring.

The company has engaged in five funding deals, with its latest round occurring on August 10, 2022, where it raised JPY 169. 000 mn from investors including EPS Holdings and ONO PHARMACEUTICAL. The current valuation stands at JPY 5008. 900 mn.

Alice Hubbard is the founder of the company, and the current CEO is Enayat H, Ichiro Amimori. Xenoma Inc. specializes in innovative healthcare services utilizing its core product, the e-skin smart apparel. This technology enhances daily health monitoring, allowing users to engage in comfortable, at-home assessments such as the e-skin ECG for Holter electrocardiogram tests.

The company markets its products primarily to healthcare facilities, including hospitals and clinics, to facilitate patient monitoring and health checkups. Additionally, Xenoma offers a range of wearable health solutions that include fitness apparel and breathable masks for individual consumers and business customers across various sectors. Key geographical markets for Xenoma's products include Japan and other regions in Asia, where the demand for advanced health monitoring solutions is growing. Xenoma generates revenue through a multi-faceted business model that incorporates both B2B and direct-to-consumer sales.

The company engages in partnerships with healthcare providers to offer its e-skin ECG testing services, ensuring a steady flow of clients needing regular health assessments. Direct-to-consumer sales of its smart apparel and related products foster a diversified income stream. The flagship products, such as the e-skin ECG, are priced to reflect their advanced technology and healthcare application, supporting both individual and institutional customers and broadening the company’s market reach. In August 2022, Xenoma, Inc.

raised JPY 169. 000 mn in venture funding from Cyberdyne, Inc. , aimed at promoting the creation of new value through collaboration and technology integration. The company plans to introduce new e-skin products and expand its offerings into additional markets across Asia by the end of 2023, aligning with the growing demand for comprehensive health monitoring solutions.